Brief: CytRx Highlights Orphazyme's Update On Productive Meeting With FDA Regarding Arimoclomol In Niemann-Pick Disease Type C

LadRx

02/11/2021 12:10

Nov 2 (Reuters) - CytRx Corp  CYTR.PK :
    * CYTRX HIGHLIGHTS ORPHAZYME'S UPDATE ON PRODUCTIVE MEETING
WITH
FDA REGARDING ARIMOCLOMOL IN NIEMANN-PICK DISEASE TYPE C
    * CYTRX CORP - FDA RECOMMENDS ORPHAZYME PROVIDES
SUPPLEMENTAL
INFORMATION AND ANALYSES
    * CYTRX CORP - FDA OFFERS TO HAVE FURTHER INTERACTIONS WITH
ORPHAZYME TO IDENTIFY PATH TO RESUBMISSION FOR ARIMOCLOMOL IN
NPC
    * CYTRX CORP - FDA NOTED IN CRL THAT ADDITIONAL DATA IS
NEEDED TO
BOLSTER CONFIRMATORY EVIDENCE BEYOND SINGLE PHASE 2/3 CLINICAL
TRIAL

Source text for Eikon:  ID:nBw61lkd8a 
Further company coverage:  CYTR.PK 

 ((Reuters.Briefs@thomsonreuters.com;;))